Migraine day frequency in migraine prevention: longitudinal modelling approaches

• Published in: BMC medical research methodology Vol. 19; no. 1; p. 20
• Main Authors: Di Tanna, Gian Luca, Porter, Joshua K, Lipton, Richard B, Brennan, Alan, Palmer, Stephen, Hatswell, Anthony J, Sapra, Sandhya, Villa, Guillermo
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 23.01.2019; BioMed Central; BMC
• Subjects: Accounting; Antibodies, Monoclonal, Humanized - therapeutic use; Beta-binomial; Binomial Distribution; Calcitonin Gene-Related Peptide Receptor Antagonists - therapeutic use; Clinical trials; Cost analysis; Data Interpretation, Statistical; Economic models; Erenumab; Frequency distribution; Headaches; Humans; Medical research; Methods; Migraine; Migraine Disorders - drug therapy; Migraine Disorders - prevention & control; Migraine frequency; Modelling; Models, Statistical; Monoclonal antibodies; Negative binomial; Patients; Prevention; Quality of life; Survival analysis; Testing; Time Factors; United States; Migraine frequency; Negative binomial; Erenumab; Modelling; Beta-binomial; Migraine
• ISSN: 1471-2288; 1471-2288
• DOI: 10.1186/s12874-019-0664-5

Health economic models are critical tools to inform reimbursement agencies on health care interventions. Many clinical trials report outcomes using the frequency of an event over a set period of time, for example, the primary efficacy outcome in most clinical trials of migraine prevention is mean change in the frequency of migraine days (MDs) per 28 days (monthly MDs [MMD]) relative to baseline for active treatment versus placebo. Using these cohort-level endpoints in economic models, accounting for variation among patients is challenging. In this analysis, parametric models of change in MMD for migraine preventives were assessed using data from erenumab clinical studies. MMD observations from the double-blind phases of two studies of erenumab were used: one in episodic migraine (EM) (NCT02456740) and one in chronic migraine (CM) (NCT02066415). For each trial, two longitudinal regression models were fitted: negative binomial and beta binomial. For a thorough comparison we also present the fitting from the standard multilevel Poisson and the zero inflated negative binomial. Using the erenumab study data, both the negative binomial and beta-binomial models provided unbiased estimates relative to observed trial data with well-fitting distribution at various time points. This proposed methodology, which has not been previously applied in migraine, has shown that these models may be suitable for estimating MMD frequency. Modelling MMD using negative binomial and beta-binomial distributions can be advantageous because these models can capture intra- and inter-patient variability so that trial observations can be modelled parametrically for the purposes of economic evaluation of migraine prevention. Such models have implications for use in a wide range of disease areas when assessing repeated measured utility values.